StockData
Telomir Pharmaceuticals, Inc. logo

Telomir Pharmaceuticals, Inc. (TELO) stock

TELONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 6/30
$0.42−0.06 (-12.04%)

Close on Nov 17, 2026Market cap $29.10MP/E –Yield –

Telomir Pharmaceuticals operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Telomir Pharmaceuticals's operating cash flow for the twelve months ending Sep 30, 2026 was -$4.57M. For fiscal 2025 it was -$3.69M.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$3.69M–
FY2024Dec 31, 2024-$5.07M–
FY2023Dec 31, 2023-$3.86M–
FY2022Dec 31, 2022-$468.66K–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$586.44K–
Q2 FY2026Jun 30, 2026-$1.01M–
Q1 FY2026Mar 31, 2026-$1.77M–
Q4 FY2025Dec 31, 2025-$1.20M–
Q3 FY2025Sep 30, 2025-$927.26K–
Q2 FY2025Jun 30, 2025-$696.45K–
Q1 FY2025Mar 31, 2025-$863.13K–
Q4 FY2024Dec 31, 2024-$605.81K–
Q3 FY2024Sep 30, 2024-$1.00M–
Q2 FY2024Jun 30, 2024-$1.52M–
Q1 FY2024Mar 31, 2024-$1.94M–
Q4 FY2023Dec 31, 2023-$1.09M–
Q3 FY2023Sep 30, 2023-$2.00M–
Q2 FY2023Jun 30, 2023-$33.58K–
Q1 FY2023Mar 31, 2023-$735.74K–

More Telomir Pharmaceuticals figures

See a number that looks wrong?